Analysts: U.S. Bancorp a Buy on Weakness, and 3 More Research Notes to Check Out
U.S. Bancorp (NYSE:USB): RW Baird would recommend opportunistic buyers to take advantage of any weakness in U.S.Bancorp. The firm believes it remains a core holding, citing growth opportunities, disciplined capital management, and consistent returns on investment. The firm rates the shares Outperform with a $39 price target.
Cliffs Natural (NYSE:CLF): Cowen upgraded Cliffs Natural to Market Perform from Underperform. The firm’s upgrade is based on discounted valuation, a new management team, and possible structural changes. Cowen pegged a $20 price target on the shares.
St. Jude Medical (NYSE:STJ): Canaccord has increased concerns following St. Jude’s third quarter results and management commentary, noting that management was less bullish regarding products, gross margins were lower, and more non-recurring expenses are expected in the fourth quarter. The firm views shares as overvalued relative to earnings expectations, poor organic growth drivers, and slow-growth markets. Shares of St. Jude are Sell rated with a $42 price target, up from $40.
Regeneron (NASDAQ:REGN): RBC Capital expects third quarter sales of Regeneron’s Eylea to be in-line with the consensus estimate, but the firm thinks that any pause in Eylea growth is short-lived, and will be more than offset by several fundamental drivers; the firm expects the company’s top and bottom lines to grow 25 percent – 30 percent, and it keeps an Outperform rating on the shares.